Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7503736 | 0.90 | HRH3 (0.44) | HRH3ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL1052899 | 0.87 | HRH3 (0.48) | HRH3ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL7749087 | 0.84 | SMN1; SMN2 (0.55) | HRH3ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL7879735 | 0.84 | HRH3 (0.51) | HRH3ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL31075110 | 0.83 | HRH3 (0.48) | HRH3ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL25698055 | 0.83 | HRH3 (0.50) | HRH3ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL22075873 | 0.82 | HRH3 (0.39) | HRH3ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL46308 | 0.81 | HRH3 (0.49) | HRH3ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL7454861 | 0.81 | HRH3 (0.49) | HRH3ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL19931764 | 0.81 | HRH3 (0.49) | HRH3ALDH1A1MEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118146165-A | 2,3, 5-Trisubstituted pyrazine compound and preparation method and application thereof | 郑州大学 | 2024-06-07 | — | — | CN | claimed |
| CN-113968824-B | 2,3, 5-trisubstituted pyrazine compound and preparation method and application thereof | 郑州大学 | 2024-01-19 | — | — | CN | claimed |
| CN-113968824-A | 2,3, 5-trisubstituted pyrazine compound and preparation method and application thereof | 郑州大学 | 2022-01-25 | — | — | CN | claimed |
| WO-2025085819-A1 | KINASE INHIBITOR COMPOSITIONS AND RELATED METHODS FOR THE TREATMENT OF A DISEASE | WASHINGTON UNIVERSITY (US) | 2025-04-24 | — | — | WO | disclosed |
| CN-119462522-A | N2-3-Fluoro-5-substituted phenyl-2-aminopyrimidine derivative, preparation method and medical application thereof | 浙江大学 | 2025-02-18 | — | — | CN | disclosed |
| US-20240366809-A1 | INHIBITOR OF PROSTATE SPECIFIC MEMBRANE ANTIGEN AND PHARMACEUTICAL USE THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2024-11-07 | — | — | US | disclosed |
| CN-118666837-A | GPX4 protein degradation agent, preparation method and application thereof | 首都医科大学 | 2024-09-20 | — | — | CN | disclosed |
| CN-118388414-A | Pyridazinone compound and preparation method, pharmaceutical composition and application thereof | 中国药科大学 | 2024-07-26 | — | — | CN | disclosed |
| CN-118359600-A | Aryl imidazolyl isoxazole compound as well as preparation method and application thereof | 中国科学院广州生物医药与健康研究院 | 2024-07-19 | — | — | CN | disclosed |
| WO-2024149239-A1 | HETEROAROMATIC CYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翊维康医药有限责任公司 | 2024-07-18 | — | — | WO | disclosed |
| EP-4397322-A1 | INHIBITOR OF PROSTATE SPECIFIC MEMBRANE ANTIGEN AND PHARMACEUTICAL USE THEREOF | Tianjin Hengrui Medicine Co., Ltd. (CN) | 2024-07-10 | — | — | EP | disclosed |
| WO-2005051304-A2 | AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2005-06-09 | — | — | WO | disclosed |
| US-20050043347-A1 | Thienopyridine and furopyridine kinase inhibitors | ABBVIE INC. | 2005-02-24 | — | — | US | disclosed |
| CN-1178905-C | Novel peptide derivative | — | 2004-12-08 | — | — | CN | disclosed |
| CN-1099425-C | Novel peptide derivatives | ASTRAZENECA AB (SE) | 2003-01-22 | — | — | CN | disclosed |
| US-6114328-A | ANTICOAGULANTS; BLOOD DISORDERS | DUPONT PHARMACEUTICALS COMPANY (US) | 2000-09-05 | — | — | US | disclosed |
| US-5849736-A | Isoxazoline and isoxazole fibrinogen receptor antagonists | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-12-15 | — | — | US | disclosed |
| EP-0832076-A1 | NOVEL ISOXAZOLINE AND ISOXAZOLE FIBRINOGEN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-04-01 | — | — | EP | disclosed |
| WO-1996038426-A1 | NOVEL ISOXAZOLINE AND ISOXAZOLE FIBRINOGEN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-12-05 | — | — | WO | disclosed |
| CN-1127509-A | Novel peptide derivatives | ASTRA AB (SE) | 1996-07-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366809-A1 | INHIBITOR OF PROSTATE SPECIFIC MEMBRANE ANTIGEN AND PHARMACEUTICAL USE THEREOF | KLK3, MAN2B2, ACP3 | HRH3 2439/4885ALDH1A1 2180/4885MEN1 360/4885 |
| US-20050043347-A1 | Thienopyridine and furopyridine kinase inhibitors | ABL1, ERBB2, LCK | HRH3 1407/4885ALDH1A1 1899/4885MEN1 2197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.